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ABSTRACT
Soon aft er discovery of RNA interference (RNAi), its potential as eff ective antiviral therapy was recognized. Since then 
RNAi has been variously exploited for antiviral purposes which could eff ectively block viral replication in vitro. For in 
vivo use, however, delivery issue, toxicity, RNAi suppression and viral escape are still major hurdles. Here, we provide 
an overview of the RNAi strategy and review the approaches that have been developed to surpass the obstacles and to 
achieve targeted gene silencing for antiviral and other therapies.   
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INTRODUCTION
 RNAi is a highly specifi c, evolutionarily 
conserved, post transcriptional gene silencing mechanism 
used by cells for gene regulation, protection of genome 
against transposable elements and the attack of RNA 
viruses. While RNAi acts as an important innate antiviral 
defense mechanism in plants and insects (Zamore et al. 
2000; Hamilton & Baulcombe 1999), whether RNAi as 
antiviral immune mechanism really exists in mammals, 
remains unclear (Haasnoot & Berkhout 2010; Umbach 
& Cullen 2009). However, the enzymatic machinery 
for RNAi is used by the other endogenous non-coding 
small RNAs like microRNAs (miRNAs), for regulation of 
gene expression (Pfeifer & Lehman 2010; Hajeri & Singh 
2009). It is estimated that RNAi mediated gene regulation 
controls the expression of about 30% of mammalian 
genes, many of which are involved in functions like cell 
fate, proliferation and death (Lewis et al. 2005).
Discovery
 Th e phenomenon of RNAi was fi rst observed by 
Napoli and colleagues in 1990, when they were trying to 
over express an enzyme responsible for plant coloration 
by introduction of the exogenous gene in petunias (Napoli 
et al. 1990). Surprisingly, the introduced gene resulted in a 
blockage of pigment synthesis. Th e phenomenon of gene 
suppression, however, was not understood at that time. It 
was Andrew Fire and Craig Mello who fi nally established 
the mechanism in 1998, by demonstrating that injection 
of short stretches of 23mer to 25mer nucleotides 
sequence of double stranded RNA (dsRNA) into the 
nematode Caenorhabditis elegans resulted in silencing of 
endogenous genes (Fire et al. 1998).  Fire and Mello were 
awarded the Nobel Prize for Medicine or Physiology in 
2006 for their discovery. Th is mode of gene silencing was 
diff erent from the already established anti-sense mode 
of gene silencing in that, although both are based upon 
sequence complementarity to messenger RNA (mRNA), 
RNAi has a catalytic component that makes it possible 
for a single small interfering RNA (siRNA) molecule 
to bind with and destroy thousands of copies of mRNA 
molecules and thus is 1000 times more eff ective than 
antisense oligonucleotides (ODNs) in silencing target 
gene (Grunweller et al. 2003; Miyagishi et al. 2003; 
Bertrand et al. 2002).  Subsequently, it was reported that 
RNAi could take place in numerous other organisms 
including invertebrates, and vertebrates (Elbashir et 
al. 2001). Elbashir and colleagues in 2001, showed that 
transfection of synthetic siRNAs could silence genes in 
mammalian cells (Elbashir et al. 2001). Since then RNAi 
has found widespread applications ranging from use in 
functional genomics and gene knock-down, to treatment 
of various medical conditions like macular degeneration, 




 RNAi machinery in mammals and plants is used intrinsically by microRNAs (miRNAs) for regulation of 
gene expression. The miRNAs are small non-coding RNA molecules transcribed by polymerase II as long primary 
transcripts or pri-miRNAs (Lee et al. 2004). The pri-miRNAs undergo a sequential maturation process in which they 
first bind to a microprocessor, a complex of two proteins in the nucleus which contains the DiGeorge Syndrome 
Critical Region-8 (DGCR8) protein and a nuclear RNase III called Drosha (Lee et al. 2003; Han et al. 2004; Denlí 
et al. 2004). Next the Drosha cleaves pri-miRNAs into pre-miRNAs, which are the imperfectly paired stem-loop 
miRNA precursors having 60 to 80 nucleotides. The pre-miRNAs are then exported to the cytoplasm by Ran GTP-
dependent Exporting-5 transporter (Lund et al. 2004; Yi et al. 2003). The Dicer (an RNase III family enzyme) at 
first, interacts with its double stranded RNA-binding protein partner (TAR RNA binding protein; TRBP) and other 
partners to cleave pre-miRNAs into mature double-stranded miRNAs of 19-25 bp with 2 nucleotide 3’ overhangs 
(Lee et al. 2002b). Then, Dicer together with R2D2 protein and its partners, couple with miRNAs duplex to form 
RISC loading complex (RLC), which helps in the loading of the miRNA duplex into another multiprotein complex, 
having Argonaute protein as its core component. This new complex is called RNA-induced silencing complex (RISC) 
or miRNA protein complex (miRNP) (Chendrimada et al. 2005; Hajeri & Singh 2009). After attachment to RISC, 
the passenger strand of miRNA is lost, while antisense strand guides RISC to the target mRNA. The miRNAs pair 
perfectly or imperfectly with the target mRNAs and thus may either result in endonuclease Argonaute 2 mediated 
cleavage and destruction of guide strand-mRNA duplex or blockage ribosome movement halting mRNA translation, 
respectively (Eulalio et al. 2008). 
Figure 1. Mechanism of RNA interference.
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 The degree of miRNA-mRNA complementarity 
has been considered to be the key determinant of the 
regulatory mechanism. Thus, in case of a perfect match, 
mRNA is cleaved by RISC, while central mismatches 
may result in repression of mRNA translation (Pfeifer 
& Lehman 2010). Based on recent developments in 
understanding miRNA biology and mechanisms, at least 
three main models can be proposed by which miRNAs 
could modulate gene expression post-transcriptionally: 
(1) inhibition of translation initiation, (2) postinitiation 
inhibition of translation, and (3) mRNA degradation 
(Li & Rana 2012). Two others endogenous small RNA 
species have been identified, as piwi-interacting RNAs 
(piRNAs), and endogenous siRNAs (endo-siRNAs). 
piRNAs are germ cell-specific and have been shown to 
regulate transposon activities and spermatogenesis in 
Drosophila melanogaster (Klattenhoff & Theurkauf 2008). 
Endo-siRNAs are also involved in transposon silencing in 
Drosophila, Caenorhabditis elegans and mammals (Czech 
et al. 2008). 
 Plasmid or viral vectors expressing short 
hairpin RNAs (shRNAs) and chemically synthesized 
siRNAs mimic mammalian pre-miRNAs and miRNAs 
respectively and thus use cellular machinery for gene 
silencing. The only difference being that, the antisense 
strand of siRNA, acting as a guiding strand pairs 
perfectly with the target mRNA resulting in RISC-
mediated cleavage of the target mRNA (Elbashir et al. 
2001). Viral/plasmid vector based shRNAs, transcribed 
from a polymerase III promoter, are produced in the 
nucleus and exported to the cytoplasm by exportin-5 
together with GTP-bound form of its cofactor Ran, and 
are processed by Dicer like pre-microRNAs to produce 
siRNAs (Yi et al. 2003). A schematic representation of 
RNAi mechanism is shown in Figure 1.
Interfering RNAs as an antiviral therapeutics
 Targeting viral mRNA with siRNA is an attractive 
strategy since firstly, one can prevent synthesis of critical 
viral proteins to disrupt viral life cycle, secondly with 
siRNAs, being highly specific, there is little chance of 
side effects, and finally, understanding of gene function 
is not required: only viral genome sequences are needed 
(Spurgers et al. 2008). Soon after discovery of RNAi, its 
potential as effective antiviral therapy was recognized. 
RNAi antiviral treatment was first used by Bitko and Barik 
in 2001 against respiratory syncytial virus (RSV) (Bitko & 
Barik 2001). Since then the approach has been variously 
exploited for antiviral purposes, not only through the use 
of chemically synthesized siRNAs but also by expressing 
the shRNAs from plasmid or viral vectors (McCaffrey 
et al. 2003; Banerjea et al. 2003; Lee et al. 2002a). RNAi 
through these various approaches could effectively block 
viral replication in vitro but for in vivo use, delivery issue 
is still a major hurdle.   
Difficulties in use of RNAi as an antiviral approach
 In addition to delivery issues, the therapeutic use 
of RNAi in vivo also faces other practical difficulties like 
off-target effects, RNAi suppression and viral escape.
Off-target effects:
 Although RNAi is highly specific, in addition 
to the intended mRNA suppression, it also produces 
unintended effects on gene expression. For in vivo 
delivery, off-target effects are major concerns since 
the down-regulation of self-genes could have serious 
biological consequences. They may result from either a 
partial sequence complementarity of RNAi construct to 
non-targeted mRNA or induction of a variety of immune 
and toxicity related effects emanating from certain motifs 
or patterns in the RNAi construct itself  (Rao et al. 2009).
Specific off-target effects dependent on siRNA 
sequences
 Although initially thought to be highly specific, 
RNAi was shown by expression profiling to produce off-
target effects whereby a particular siRNA will bind to 
other mRNAs in addition to/instead of the one originally 
targeted. Partial sequence complementarity in both the 
passenger or guide strands of RNAi construct can produce 
off-target gene suppression Jackson et al. 2003). The off-
target silencing has been reported for transcripts with 
as low as 7 nucleotides complementarity with the guide 
strand (Lin et al. 2005).  siRNAs like miRNAs can also 
bind to sequences with partial complementarity at the 3’-
UTR rather than overall homology between the siRNA 
and targets (Valencia-Sanchez et al. 2006; Birmingham 
et al. 2006; Anderson et al. 2008a).  Furthermore, both 
the siRNA and shRNA with a complementarity in the 
“seed region”, the 5´-end of the guide strand, can produce 
similar off-target expression profiles (Jackson et al. 
2006a), however shRNA is reported to induce fewer off 
target effects than siRNA (Rao et al. 2009).
Figure 2. Seed dependant off-target effect. The capability of 
siRNAs to induce seed-dependent off-target effect is highly 
correlated to the thermodynamic stability of the duplex formed 
between the seed region of siRNA guide strand and its target 
mRNA (Ui-Tei et al. 2008b; Naito et al. 2009).
Non-specific off-target effects - Induction of type 1 
interferon (IFN) and other immune responses
 The animal immune system can discriminate 
between self and non-self nucleic acids. The double-
stranded RNA (dsRNAs) longer than 30 bases can 
induce an immune response via protein kinase R 
Almeida et al.4
(PKR), resulting in a general degradation of mRNA 
and inhibition of translation as well as up regulation of 
interferon (IFN) stimulated gene expression (Bumcrot et 
al. 2006). Moreover, even the smaller (<30 nucleotides) 
siRNAs, although initially considered non-immunogenic 
(Elbashir et al. 2001), have been found to induce a partial 
cytokine and type-1 IFN response via toll like receptors 
(TLRs) (Sledz et al. 2003; Kariko et al. 2004; Hornung et 
al. 2005). It is also reported that although RNA sensing 
receptors are also found in the cytoplasm, nucleic acids 
mediate immunoactivation mainly through TLRs 7 and 
8 (activated by ssRNA), TLR9 (by unmethylated CpG 
motifs in bacterial plasmids) and TLR3 (via dsRNA) 
(Hornung et al. 2005; Judge et al. 2005; Diebold et al. 
2004; Heil et al. 2004; Karin et al. 2004). siRNA immune 
stimulation via TLR7 and TLR8 on endosomes can be 
sequence dependent and therefore is possibly avoidable 
(Hornung et al. 2005; Judge et al. 2005; Sioud 2005). 
Certain RNA sequences have been identified to be 
particularly immunostimulatory, such as “UGUGU” 
(Heil et al. 2004) and “GUCCUUCAA” (Hornung et al. 
2005). The chemically synthesized siRNAs delivered by 
transfectants enter cells through endocytosis and are 
therefore more prone to cause immune stimulation via 
TLRs 7/8 found on endosomes. Conversely, shRNAs 
expressed intracellularly by plasmid and viral vectors, 
follow more closely the endogenous RNAi pathways and 
thus prevent interferon response (Rao et al. 2009; Schlee 
et al. 2006).
Unwanted participation in miRNA pathways
 The enzymatic machinery involved in RNAi in 
mammalian cells is naturally used by miRNAs which 
play an important role in cell physiology. Since miRNA 
and shRNA share common enzymatic pathway for 
their processing, the over-expression of shRNA in vivo 
is known to produce toxicity due to over-saturation of 
endogenous miRNA pathway involving exportin-5 and 
RISC component Argonaute-2 (Grimm et al. 2006). 
However, in vivo toxicity can be alleviated by the 
selection of efficient but safe shRNA expression cassettes, 
and applying minimal effective vector doses (Grimm et 
al. 2006).
 Despite the high specificity of siRNA activity, 
some mismatches are often tolerated and can still reduce 
expression of off-targeted genes (Du et al. 2005), (Dahlgren 
et al. 2008). Consequently, even carefully screened 
siRNAs can cause significant changes in expression of 
unrelated genes (Persengiev et al. 2004; Scacheri et al. 
2004). Many of these off-target effects are mediated by 
the participation of siRNAs in miRNA pathways (Behlke 
2008). The miRNA translational suppression pathway is 
directed by imperfect base pairing between target gene 
and guide strand of the miRNA and the specificity of this 
process is defined by 6-7 bases at the 5’-end (seed region) 
of the latter (Doench & Sharp 2004; Lin & Feng 2005; 
Jackson et al. 2006a). Consequently, 6-7-base matches 
between a siRNA and non-targeted gene can mediate an 
off-target effect by the miRNA translational suppression 
pathway (Birmingham et al. 2006). Homology screening 
of the seed region of siRNA candidates with all genes 
seems to be prudent (Anderson et al. 2008b).
Passenger strand activity
 Only functional participation of the guide strand 
of the double-stranded siRNAs is desired. Nevertheless, 
some variable amount of the passenger strand can be 
loaded into RISC and trigger off-target gene-knockdown 
(Clark et al. 2008). Asymmetric 25-nt/27-nt siRNA can be 
designed to preferentially load its guide strand decreasing 
then the potential off-target effects from the passenger 
strand (Rose et al. 2005). Dual-targeting siRNAs can 
be also designed targeting different sites within a single 
mRNA or two separate mRNAs target. These siRNAs 
may reduce the potential for off-target gene silencing, 
increase the opportunity to knockdown the desired 
target gene(s), and potentially provide synergistic effects 
by both strands (Tiemann et al. 2010).
Viral encoded suppressors of RNAi 
 Several plants and invertebrates use RNAi as an 
immune mechanism to counter viral infections (Zamore 
et al. 2000; Hamilton & Baulcombe 1999). Therefore, 
viruses infecting these plants and insects have evolved 
their countermeasures by producing various suppressors 
of RNAi silencing (SRS) (Voinnet et al. 1999; Li et al. 2002). 
Some recent studies suggest that RNAi in mammals is also 
involved in antiviral responses and cellular regulatory 
miRNAs have a function in restricting virus replication 
in the cells (Haasnoot & Berkhout 2010). Moreover, 
several mammalian viruses like hepatitis C virus (HCV), 
influenza virus, Ebola virus, human immunodeficiency 
virus (HIV), vaccinia virus, and adenoviruses type 2 and 
5 are known to produce SRS factors that inhibit the RNAi 
mechanism. Many of these factors are multifunctional 
proteins which are known to inhibit interferon response 
as well (Haasnoot & Berkhout 2010; Umbach & Cullen 
2009). Since the viruses producing SRS can be efficiently 
inhibited by RNAi, it appears that viral-suppression 
activity does not pose a serious difficulty for therapeutic 
RNAi (Haasnoot et al. 2007). 
Viral escape
 Several applications of a single siRNA can lead to 
the emergence of viral escape mutants due to mutations 
in the target sites making viral genomes resistant to 
RNAi  (Boden et al. 2003). Since, unlike eukaryotic DNA 
polymerase, RNA viruses lack proofreading activity, they 
tend to have a high error rate during replication which 
facilitates development of viral mutants (Coffin 1995). 
After discovery of RNAi, an early study by Jacque and 
colleagues (Jacque et al. 2002), showed that even a single 
nucleotide mismatch in the siRNA target region may 
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be sufficient to reduce the silencing effect of an siRNA 
on HIV-1. Interestingly, viral escape to RNAi can also 
occur by a point mutation outside the target sequence 
of siRNA, if this mutation changes local RNA folding 
into a structure that reduces the accessibility of the 
target sequence (Westerhout et al. 2005). Several viruses 
have been reported to escape suppression by effective 
siRNAs, which include HIV-1, HCV, HAV, peste des petits 
ruminants virus (PPRV) and Poliovirus (von Eije et al. 
2008; Wilson & Richardson 2005; Kusov et al. 2006; Gitlin 
et al. 2005).  Studies of HIV-1 and HBV populations have 
shown that many resistant mutants may pre-exist before 
they have been exposed to inhibitors and the siRNAs 
may also exert selection pressure on these pre-existing 
resistant mutants (Najera et al. 1995; Wu et al. 2005). 
 The problem of RNAi escape can be more 
severe in chronic diseases as these require an extended 
antiviral therapy but may be less crucial in treatment of 
acute diseases (Haasnoot et al. 2007). However, design 
and selection of siRNAs targeting conserved regions 
of virus and combination of siRNAs targeting multiple 
genes or regions in viral genome can help avoid problem 
of resistance to siRNA therapy (Khaliq et al. 2010). 
In a study using a T cell line expressing three potent 
shRNAs against HIV-1, it was found that even after an 
extended culturing for more than 100 days there was no 
viral replication (von Eije et al. 2009). The emergence of 
escape mutants of PPRV was prevented after 20 passages 
in cell culture in presence of three combined siRNAs 
(Holz et al. 2012). A combination of four shRNAs that 
target different sequences of HBV genome has entered a 
phase I clinical trial (Castanotto & Rossi 2009). However, 
use of multiple siRNA/shRNA doses must be optimized 
before use as some studies have shown that it is possible 
to saturate the RNAi pathway with high levels of shRNA 
expression (Grimm et al. 2006). Another possible 
alternative to targeting multiple conserved viral genomic 
regions is to use siRNAs that recognize the mutated target 
sites through use of siRNAs or shRNAs that target the 
most likely escape variants (Ter Brake & Berkhout 2005). 
Since viruses tend to mutate, an alternative means could 
be to down-regulate cellular factors which are required 
by the virus to either enter a cell or to replicate. 
In vivo delivery of interfering RNAs
 Compared to the large number of studies using 
siRNAs in cell culture, there have been relatively few 
studies in vivo. The progress is slower due to difficulties 
in delivery, especially by systemic route of administration 
(Dykxhoorn et al. 2006). The issue of drug delivery is not 
unique to RNAi based therapeutics, but here it is a major 
obstacle as the drug cargo (siRNA) is nuclease sensitive, 
has a net negative charge, and is hydrophilic, thus making 
difficult to keep it stable in serum and capable of crossing 
the anionic and hydrophobic plasma membranes (de 
Fougerolles et al. 2007; Robbins et al. 2008; Czauderna et 
al. 2003). In order to use RNAi as an antiviral approach, 
the siRNAs can either be chemically synthesized (Bitko & 
Barik 2001) or shRNA expression cassettes with Poll III 
promoters can be inserted into plasmid (McCaffrey et al. 
2003) or viral vectors (Banerjea et al. 2003; Uprichard et 
al. 2005). The viral vectors can efficiently use their own 
machinery to reach the target cells, transfer their genome 
into the cells and express shRNA molecules.
 In theory, naked siRNAs and plasmid vectors 
cannot readily cross the cell membrane and therefore 
need delivery vehicles to help them to enter the cell 
cytoplasm. However, systemic delivery of naked siRNA 
into the bloodstream is being tested for siRNA delivery 
to the kidney, liver, and some solid tumors. Similarly, 
the naked siRNA can be injected directly into the target 
tissue, tumor or lesion. Tissues such as eye, lung, skin 
are suitable for topical delivery of sRNA (Whitehead 
et al. 2009). Bitko and colleagues successfully 
delivered naked siRNAs intranasally in a mouse model 
against respiratory syncytial virus (Bitko et al. 2005). 
Interestingly, they compared delivery of siRNA with and 
without a transfection reagent, and noted only a marginal 
enhancement (20%) in the knockdown of the respiratory 
syncytial virus (RSV) target gene when lipid agent was 
used. However, the mechanism by which these cells take 
up these siRNA molecules remains unknown (Wu & 
McMillan 2009). The systemic delivery route, however, 
is more difficult to approach. The unmodified siRNA 
has a half-life of less than an hour in human plasma and 
the siRNA molecules circulating in blood, are rapidly 
excreted by kidneys due to their small size (Layzer et al. 
2004). Moreover, recognition of naked siRNAs by the 
phagocytic system is associated with immunological 
and cytotoxic stimulation, that could occur right after 
injection through activation of circulating mononuclear 
phagocytosis or inside the cytoplasm and endosome 
compartments of the target cell (Daka & Peer 2012). The 
vectors are therefore needed not only to improve the 
bio-availability of siRNAs but also to provide protection 
from nucleases and help in penetration of anionic plasma 
membranes (Li et al. 2006; Feng et al. 2008).
Physical methods of siRNA delivery
 The physical methods for in vivo delivery of 
siRNA involve mainly electroporation and hydrodynamic 
injection. The hydrodynamic injection involves a quick 
injection of siRNA or plasmid DNA (pDNA) in a large 
volume of physiological buffer, around one-tenth the 
mass of the animal, within a few seconds in the tail vein 
of the animal and this results in a delivery mainly to the 
liver (Budker et al. 2006; Tada et al. 2006). McCaffrey 
and colleagues in 2002 in their studies on in vivo siRNA 
delivery by hydrodynamic method, demonstrated that 
co-injection of luciferase expressing plasmid with siRNA 
targeting luciferase produced efficient silencing of 
luciferase expression in the mouse liver (McCaffrey et al. 
Almeida et al.6
2002). Various studies using this method could deliver 
naked siRNA to hepatocytes, demonstrating functional 
knockdown of specific genes in the livers of mice 
(McCaffrey et al. 2002; Zender & Kubicka 2007; Lewis 
& Wolff 2007). Most studies are using hydrodynamic 
method for delivery of siRNA to liver as it can be much 
more easily transfected by this method as compared 
to other organs. This procedure is not clinically viable 
because of  potential damage to liver, as well as due to 
danger of volume overload side effects like right sided 
heart failure (Weinstein & Peer 2010).  Moreover, it 
would be impossible to scale up this method for use in 
humans or large animals. 
 The electroporation involves administration of 
an electric current for short duration, which temporarily 
increases the permeability of cell membranes, and thus 
allowing for passing of nucleic acids through membranes. 
The electric field polarizes the membrane molecules 
and temporarily destabilizes the membrane integrity, 
which results in greater permeability for the exogenous 
materials (Heller & Heller 2006). This technique has been 
successfully used to transfer siRNAs locally (Golzio et al. 
2007), but it cannot be used for systemic administration. 
Similarly, ultrasound is also used for nucleic acid delivery 
(Taniyama et al. 2002). These physical methods of 
delivery of siRNAs either cannot be used systemically or 
are too dangerous for clinical use.  
Chemical vectors for delivery
 The development of chemical vectors for 
siRNA delivery has been influenced by the studies on 
intracellular DNA delivery (Lu et al. 2009). However, 
there are important differences between delivery of 
siRNA and DNA: i) size and charge of siRNA are lower 
than those of DNA; ii) cytosol is the place of action for 
siRNA while DNA has to enter nucleus to be effective 
(Schroeder et al. 2010).
 The chemical methods of siRNA delivery involve 
formulation of negatively charged siRNA molecules 
with various polycations, like cationic lipids, peptides, 
polymers, or inorganic nano-structured materials, either 
through electrostatic or ionic interactions, with the 
aim of enhancing pharmacokinetic behavior, nuclease 
resistance, cellular uptake, target specificity and safety 
(Misra et al. 2010). The general principle is based on 
complex formation between anionic siRNA molecules 
and cationic polymers resulting in complexes with net 
positive charge for facilitating interaction with anionic cell 
membranes. Moreover, the physico-chemical properties 
of the complexes like size, morphology, surface charge 
and stability, are the major determinants of transfection 
efficiency which in turn are determined by structure of 
polycation, the polycation/nucleic acid stochiometry 
(+/- charge ratio), pH and order of mixing of nucleic 
acids and the vectors (Issa 2006).  Though most delivery 
vectors are cationic, the net surface charge of the vector-
siRNA complex, has to be near neutral to avoid toxicity, 
excessive uptake by reticulo-endothelial system (RES) 
and aggregation by serum proteins (Misra et al. 2010; 
Rao 2010). In order to deliver siRNA cargo into target 
cell cytoplasm, the formulation has to surpass various 
physiological barriers (Fig. 3) by shielding siRNA from 
serum nucleases, avoiding aggregation by anionic serum 
proteins, escaping from RES, penetrating endothelium, 
getting internalized through endocytosis, and finally 
being able to deliver siRNA from the endosomes to the 
cytoplasm before degradation by lysosomes (Misra et al. 
2010; Rao 2010). The in vivo use of siRNA by chemical 
delivery systems is limited by siRNA packaging efficiency, 
colloidal stability of the complex, internalization, and 
endosomal escape (Reischl & Zimmer 2009). 
Figure 3. Main physiological barriers to in vivo delivery of 
siRNA. Once in the bloodstream, siRNA must avoid aggregation 
by serum proteins, degradation by serum nucleases, filtration 
and phagocytosis; be transported across the vessel wall; 
diffuse through the extracellular matrix surpassing tissue 
barriers; be taken up into the cell; escape the endosome; and 
to be dissociated from its carrier and released to the cellular 
machinery. 
 The chemical vectors used for siRNA delivery 
can be broadly divided into three major groups: lipids, 
cationic polymers, and peptides.
Lipids as nucleic acid delivery vectors 
 Phospholipids which are a major component 
of cell membranes, tend to form spontaneous spherical 
structures called liposomes upon contact with water 
(Bangham et al. 1965). Felgner and colleagues (Felgner 
et al. 1987) were first to demonstrate the effective use of 
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liposomes for in vitro transfection of DNA. These liposomes 
were based on a cationic lipid called  DOTMA (N-[1-
(2,3,-dioleyloxy)propyl]-N,N,N-trimethylammonium 
chloride) (Felgner et al. 1987). Since then, many natural 
as well as synthetic cationic lipids have been developed 
and used for delivery of nucleic acids including DNA, 
antisense oligonucleotides and siRNAs. The preparation 
of these new cationic lipids involved either modification 
of the nature of cationic lipids (Felgner et al. 1994), fatty 
acid side chains (Rosenzweig et al. 2000), or formulations 
with some additional lipids (Budker et al. 1996). Despite 
initial difficulties found in in vivo transfection, the death 
of a human patient participating in gene therapy trials 
based on an adenoviral vector in 1999 (Raper et al. 2003) 
and the resulting temporary ban on use of viral vectors 
for gene therapy by US Food and Drug Administration 
(Couzin & Kaiser 2005), lead to a renewed interest in 
chemical vectors. 
 Typically, the cationic lipid molecules are 
amphiphilic or amphipathic in nature and are made up of 
three parts: a cationic head-group, a hydrophobic anchor, 
and a linker (Fig. 4a and 4c). The cationic head-group is 
required for binding to and complexation with nucleic 
phosphate groups, whereas hydrophobic part probably 
assists in assembling the lipids into polycationic scaffold 
and facilitating absorptive endocytosis or fusion with 
plasma membranes (Eliyahu et al. 2005). The cationic lipids 
are classified on the bases of number of positive charges, 
nature of linker bond, and nature of hydrophobic anchor 
(Eliyahu et al. 2005). Although cationic lipids are the most 
common lipids used for liposome based transfections, 
often neutral and/or anionic lipids are mixed with these 
in variable ratios to neutralize excessive cationic charge 
and to improve endosomal escape (Zhang et al. 2004). 
The anionic lipids, when added to nucleic acid-cationic 
liposome complexes, not only reduce cellular toxicity but 
also reduce nonspecific interaction with anionic serum 
proteins like albumin as well as extracellular matrix (Lee 
& Huang 1996; Mastrobattista et al. 2001). Mastrobattista 
and colleagues in 2001 were able to improve transfection 
by preparing positively charged polyplexes coated with 
an anionic lipid (Mastrobattista et al. 2001). 
 The neutral lipids play a role of a helper 
when formulated with cationic lipids for preparation 
of liposomes. There are three neutral lipids which 
are often incorporated in the formulations: dioleyl 
phosphatidylethanolamine (DOPE), cholesterol and 
dioleoyl phosphatidyl choline (DOPC). The DOPE is 
known to destabilize lipid bilayers and is believed to 
be involved in endosomal disruption and thus enabling 
nucleic acids to escape endosomes before being destroyed 
by lysosomes (Farhood et al. 1995). Cholesterol is also 
used as a helper lipid. Although it forms more stable 
but less efficient complexes with nucleic acids than 
those containing DOPE in vitro, cholesterol containing 
lipoplexes show higher biological activity due to greater 
cell uptake and stability in serum, compared to lipoplexes 
with DOPE when these complexes are utilized in vivo 
(Eliyahu et al. 2005). The liposome mediated transfection 
has been shown to take place mostly by endocytosis (Lu et 
al. 2009). However, probably a minor pathway mediated 
by fusion between siRNA containing lipoplexes and the 
plasma membrane is responsible for around 5% of siRNA 
delivery in to cell cytoplasm (Lu et al. 2009). 
Cationic liposomes 
 Liposomes are vesicles composed of a 
phospholipid bilayers with an aqueous core (Reischl & 
Zimmer 2009). They are classified according to their size 
and their number of bilayers: Small Unilamellar Vesicles 
(SUV), Large Unilamellar Vesicles (LUV), Multilamellar 
Vesicles (MLV), and Giant Unilamellar Vesicles (GUV) 
(Fig. 4b) (Lorin et al. 2004). The complex formation 
between anionic phosphate group from nucleic acids and 
cationic amine head group of cationic liposomes results 
in formation of lipoplexes, which are quite different from 
liposomes in structure as the final charge as well particle 
size changes and these changes are determined largely by 
lipid / nucleic acid (+ / -) ratios (Pires et al. 1999). 
Figure 4.  Structure of a cationic liposome. (a) formed by 
phospholipids in an aqueous medium (Boutet 2007); (b) 
Classification of liposomes according to size and number 
of bilayers (Lorin et al. 2004); (c) Representative structure 
of cationic lipid DOTMA, modified (Karmali & Chaudhuri 
2007).
In vivo delivery of siRNA with liposomes
 DOTAP (N-[1-(2,3-dioleoyloxy)]-N-N-N 
trimethyl ammonium propane) and Oligofectamine were 
some of the first lipid formulations used for in vivo delivery 
of siRNA and effective gene silencing of TNF-alpha 
and beta-catenin in mice (Verma et al. 2003; Sorensen 
et al. 2003). Since then siRNAs have been successfully 
delivered locally but there are not many reports of 
successful systemic liposome based delivery of siRNAs 
against systemic viral infections. However, there are some 
studies showing promising results in terms of successful 
delivery of siRNAs and effective viral suppression in vivo 
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by formulations based up on neutral lipids. For example, 
Morrissey and colleagues (Morrissey et al. 2005) using 
three daily intravenous injections in mice of siRNA (3 
mg/kg/day) complexed with the neutral liposomes called 
“stable nucleic acid-lipid particles” (SNALPs) stabilized 
with PEG (polyethylene glycol) , could reduce serum DNA 
of  hepatitis B virus by more than 1.0 log10 and the effect 
lasted for up to 7 days after dosing. In another experiment 
using intraperitoneal delivery of siRNAs complexed with 
SNALPs for seven days against Ebola virus has been 
shown to protect guinea pigs against viremia and death 
shortly after the virus challenge (Geisbert et al. 2006). 
Using a lactosylated liposome based upon neutral lipid 
the phosphatidylcholine, Watanabe and colleagues in 
2007 could effectively deliver siRNA targeting hepatitis 
C virus (HCV) in a transgenic murine model, resulting 
in suppression of intrahepatic HCV expression without 
interferon response (Watanabe et al. 2007). SNALPs 
developed by Protiva Biotherapeutics and Alnaylam, 
have also been successfully used to deliver siRNA in non-
human primates, whereby using a SNALP-formulated 
siRNA dose of 2.5 mg/kg, could markedly suppress the 
Apolipoprotein B (APOB) (Zimmermann et al. 2006). 
Another siRNA-lipoplex referred to as AtuFECT01 
(AtuPLEX) was used intravenously in mice (Santel et 
al. 2006). This designed cationic lipid contains neutral 
fusogenic and PEG-modified lipid components, for 
improved pharmacokinetic properties, cellular uptake, 
and efficient siRNA release from the endosomes after 
endocytosis. This complex is characterized by a highly 
charged head group, which allows for more efficient 
siRNA-binding as compared to other commercially 
available cationic lipids such as DOTAP or DOTMA. 
The biodistribution analysis on systemic administered 
siRNA-AtuPLEX indicated a predominantly specific 
targeting of endothelial cells in the vasculature of several 
organs after single dosing. The authors advocate that 
the potential lipid-associated toxicity of the AtuPLEX 
is also reduced (Santel et al. 2006). Novobrantseva 
and colleagues demonstrate the ability of two types of 
liposomal formulations KC2 (an ionizable lipid) and C12-
200 (a cationic lipid) to mediate silencing in nonhuman-
primate and rodent myeloid cells (Novobrantseva et al. 
2012). The high in vivo potency of these formulations 
and their ability to deliver siRNA to myeloid cells makes 
them potentially applicable for clinical use to treating 
multiple human diseases, such as modulating chronic 
inflammation in autoimmune disease, protecting 
against myeloid-tropic viral infections, reprogramming 
tumor-associated macrophages, restoring functionally 
insufficient cells, or killing malignantly transformed 
immune cells. Delivering siRNA to myeloid cells could 
provide novel approaches (Novobrantseva et al. 2012). 
Lipidoids are non-glycerol-based cationic lipid particles 
synthesized by conjugation of amines to acrylate or 
acrylamide (Akinc et al. 2008). Lipidoid-formulated 
siRNA system upon systemic administration showed 
potent and specific dose-dependent gene silencing using 
a pool of siRNA sequences targeting different genes a 
pool of five siRNA sequences (Akinc et al. 2008; Love et 
al. 2010). 
 Despite encouraging results in animal models, 
there are no known reports of non-viral delivery of 
siRNAs in farm animals. Systemic application of siRNA 
molecules by lipid based carriers is still challenging and 
issues of toxicity and need for targeted delivery still need 
to be addressed.
Cell penetrating peptides (CPPs)
 CPPs or protein transduction domains (PTDs) 
are short peptides having fewer than 30 residue peptides, 
derived from natural or unnatural protein or chimeric 
sequences (Heitz et al. 2009). Most of the CPPs possess a 
high density basic amino acids (arginines and/or lysines), 
which are proposed to interact with the anionic surface 
of the cell membrane and enhance internalization 
of the peptides (Endoh & Ohtsuki 2009). Among 
chemical delivery vectors CPPs are unique in that the 
concentrations of CPPs that are used for molecular 
delivery, produce very low or undetectable cytotoxicity 
(Endoh & Ohtsuki 2009). 
 CPPs were first discovered when Frank and 
Pabo in 1988 observed that HIV-1 Trans-Activator 
of Transcription (Tat) protein, which transactivates 
transcription of the HIV-1 genome, crossed the cell 
membrane by itself (Frankel & Pabo 1988). Later, a 
minimal peptide fragment of Tat (49-59 amino acids) 
involved in cellular uptake was identified by a French 
group (Vives et al. 1997). The Tat peptide has been 
shown to successfully deliver siRNAs in vitro (Meng et 
al. 2009). Another major discovery in CPP domain was 
a 16-mer non-viral peptide derived from the Drosophila 
Antennapedia homeodomain protein (Derossi et al. 
1994). This peptide, named PenetratinTM, is capable of 
transfecting nucleic acids, antisense oligonucleotides 
(Allinquant et al. 1995), and peptide nucleic acids 
(PNAs) (Morris et al. 1997). An MPG peptide was used 
to perform the first non-covalent delivery of nucleic 
acids in 1997 (Morris et al. 1997). The MPG peptide is 
an artificially constructed 27 amino acid amphipathic 
CPP containing a lysine rich basic region derived from 
the nuclear localization signal (NLS) of the SV40 large 
T antigen and a hydrophobic region derived from the 
HIV-gp41 coat protein (Morris et al. 1997). Both the 
MPG peptide and a modified MPGΔNLS (having a single 
mutation of the second lysine residue in the NLS motif 
to serine) can transfect siRNA in vitro however latter is 
more efficient as it delivers siRNA into cytoplasm instead 
of nucleus (Simeoni et al. 2003). MPG peptides have been 
also used to deliver siRNA into mice by systemic route 
(Crombez et al. 2009). Another milestone was achieved 
when a chimeric CPP “Transportan”, derived from 
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the N-terminal fragment of the neuropeptide galanin 
linked to a wasp venom peptide called mastoparan was 
successfully used in vivo for delivery of peptide nucleic 
acids (PNAs), in mice (Pooga et al. 1998). The first 
CPP based transfection of siRNA was performed with 
a MPG peptide (Simeoni et al. 2003) and since then 
numerous natural and as well as engineered CPPs have 
been tested for siRNA delivery (Meade & Dowdy 2007). 
Polyarginine-based peptides have also been successfully 
used for siRNA delivery. Majority of the CPPs possess 
basic amino acids (arginines and/or lysines), through 
which these interact with cell membranes and help in 
the internalization of CPPs (Endoh & Ohtsuki 2009). The 
experiments on Tat and penetratin revealed that the role 
of positive charges is crucial for translocation (Deshayes 
et al. 2005). After studying various cationic polypeptides, 
CPPs with polyarginines were found to be more efficient 
than other cationic polypeptides like polyhistidines and 
polylysines and among polyarginine peptides, Arg7 and 
Arg9 have been the most widely used for in vitro and in 
vivo delivery (Deshayes et al. 2005).
 Although cellular uptake mechanism for CPPs 
has been reported to be associated with endosomal 
pathway (Richard et al. 2003), there is no unified 
mechanism established for CPP uptake mechanism up to 
now, and probably numerous factors are involved (Heitz 
et al. 2009). However, there is a consensus that the initial 
contact between the CPPs and the cell membrane takes 
place by electrostatic interactions with negatively charged 
proteoglycans (Heitz et al. 2009). Moreover, as CPPs are 
diverse in chemical and physical structures, it is suggested 
that different properties like CPP molecule length, charge 
delocalization as well as size and charge of the cargo can 
have impact upon peptide uptake mechanism (Mueller 
et al. 2008). Cellular uptake of CPPs, therefore, does not 
occur by any single mechanism, thus energy independent 
direct diffusion, macropinocytosis, clathrin-mediated 
endocytosis, and caveloe/lipid raft mediated endocytosis 
may all occur (Duchardt et al. 2007).
 CPPs can be classified in two ways. These 
are classified either on the basis of mode of bonding 
with cargo into, those requiring covalent linkage with 
siRNAs and others which, being amphipathic, can form 
stable non-covalent bonds. Secondly, these can also be 
subdivided structurally into those which polycationic 
having clusters of polyarginine in the primary sequence 
or those which are amphipathic (Heitz et al. 2009).
Covalent attachment of CPP to siRNA
 Tat conjugated to the modified antisense strand 
of siRNA was successfully used to inhibit EGFP gene in 
vitro (Chiu et al. 2004). However, most of Tat-siRNA 
was found localized in endosomes and there was a 
concern that the attachment of Tat to siRNA may disrupt 
functionality of siRNA molecules (Juliano et al. 2008). 
To address this concern, CPPs have also been linked to 
siRNA through disulfide bond which is cleaved when 
conjugates reach reducing environment of cytosol, 
resulting in successful RNAi (Davidson et al. 2004; 
Muratovska & Eccles 2004). The covalent strategy usually 
requires complex chemistry for conjugation and there 
is also risk of alteration of biological activity of siRNA 
therefore non-covalent strategy of delivery appears more 
suitable (Heitz et al. 2009).
Non-covalent CPP-siRNA complex formation
 Assembling siRNA/CPP complexes through 
non-covalent interactions is advantageous as it simplifies 
conjugation protocols but also eliminates the need 
for optimization of individual syntheses schemes. 
Additionally, there is also lower likelihood that CPP 
will interfere with the bioactivity of the cargo (Heitz et 
al. 2009). The non-covalent delivery of siRNA is based 
up on electrostatic interactions between siRNA and 
amphipathic peptides (Endoh & Ohtsuki 2009). The 
amphipathic peptides possess hydrophobic (polar) and 
hydrophilic (non-polar) domains. The amphipathic 
property of CPPs may arise from either primary or 
secondary structure (Deshayes et al. 2005). Primary 
amphipathic peptides consists of the sequential assembly 
of a domain of hydrophobic residues with a domain 
of hydrophilic residues while secondary amphipathic 
peptides are produced by conformational state that allows 
positioning of hydrophobic and hydrophilic residues on 
opposite sides of the molecule (Deshayes et al. 2005). 
 Since siRNAs are negatively charged, they can 
bind with positively charged CPPs through nonspecific 
electrostatic interactions and provide permeability by 
covering the siRNA surface with positive charges from 
the CPP (Endoh & Ohtsuki 2009). In 2003, a non-covalent 
strategy based on MPG was found to efficiently deliver 
siRNA into cell lines (Simeoni et al. 2003). Similarly, 
this non-covalent mode of delivery has also been used 
for other CPPs like, Tat, polyarginine, and transportan-
derived peptides (Heitz et al. 2009). A novel 20-amino 
acid amphipathic peptide, CADY, has been recently 
described which combines both cationic arginine and 
aromatic tryptophan residues into its design (Crombez 
et al. 2009). It forms stable complexes with siRNA 
through electrostatic interactions and interestingly uses 
a non-endocytic mechanism to pass through plasma 
membrane, thus avoiding endosomal entrapment 
(Crombez et al. 2009). This CPP can transfect a variety 
of cell lines, including difficult to transfect primary 
cell lines (Crombez et al. 2009). Since CADY-siRNA is 
stable in 50% serum for 24 hours and leads to significant 
knockdown with sub-nanomolar concentration, it may 
be effective in vivo as well (Crombez et al. 2009).
In vivo delivery with CPPs
 CPPs have been delivered in vivo with some 
successes and failures. MPG peptide was used for 
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systemic in vivo delivery of siRNA targeting essential cell 
cycle protein cyclin B1, resulting in efficient blockage 
of tumor growth (Crombez et al. 2007). In another 
experiment, siRNA targeting HIV was successfully 
delivered through a CD7-specific single-chain antibody 
conjugated to the oligoarginine peptide (scFvCD7-9R) 
and could effectively suppress HIV infection in a mouse 
model (Kumar et al. 2008). The CD7 receptor is rapidly 
internalized after antibody binding, therefore it has been 
exploited for the targeted delivery of several monoclonal 
antibody (mAb) (Kumar et al. 2008). Kumar and 
colleagues (Kumar et al. 2008) using a nonamer arginine 
at the carboxy terminus of a peptide derived from rabies 
virus glycoprotein (RVG) were able to transfer siRNA into 
neuronal cells in vivo, resulting in efficient gene silencing 
after intravenous injection into mice. Furthermore, 
systemic delivery of RVGR9 conjugated antiviral siRNA 
complex could protect mice from encephalitis induced 
by Japanese encephalitis virus (JEV) infection, which is 
the first report on a nontoxic method of siRNA delivery 
across the blood brain barrier (Anantpadma et al. 2010). 
CPP based siRNA delivery has also entered at level of 
preclinical and clinical trials, with Traversa Inc. testing 
HIV Tat-based and Panomics Inc., testing secondary 
amphipathic peptide-based non-covalent delivery of 
siRNA (Heitz et al. 2009).
Nanoparticles (NPs)
 Numerous nanoparticles (NPs) were investigated 
for siRNA delivery including: dextran–spermine 
nanoparticles (Jiang et al. 2012), calcium phosphate 
nanoparticles (Guo et al. 2010), thioketal nanoparticles 
(Conde et al. 2012), crosslinked iron oxide nanoparticles 
(Shahzad et al. 2011), liposomal integrin target-
stabilized nanoparticles (Wang et al. 2013), galactose-
conjugated liposome nanoparticles (Jiang et al. 2012), 
etc. Among these numerous NPs formulations designed, 
those based on gold nanoparticles (AuNPs) have been 
extensively investigated to cancer genes silencing without 
undesirable immune response or off-target effects (Guo 
et al. 2010; Conde et al. 2012). Shahzad and colleagues 
showed that reconstituted high-density lipoprotein 
nanoparticles (rHDL- nanoparticles) can efficiently 
deliver siRNA in vivo to silence genes that are critical 
for cancer growth and progression without toxicity 
(Shahzad et al. 2011). Inorganic nano-particles as single-
walled carbon nanotubes (SWNTs) associated with 
other chemical molecules or peptides have been used to 
obtain promising tumor targeting siRNA delivery system 
(Wang et al. 2013). An increase in phagocytic activity is 
observed upon using highly charged NPs, prominently 
cationic, as well as hydrophobic particles. In order to 
avoid opsonization, strategies that mask the NP charge 
and hydrophobicity may be applied, such as PEGylation 
(Daka & Peer 2012). 
 Exosomes are naturally occurring, membranous 
nanovesicles of 40-100 nm in diameter. All mammalian 
cells and cell lines are thought to be competent for 
exosome production, although the yield varies from cell 
to cell (Lakhal & Wood 2011). Furthermore, exosomes 
have consistently been found in most biological fluids 
including blood, urine, cerebrospinal fluid, breast milk, 
amniotic fluid, malignant pleural effusions and ascites 
(Simpson et al. 2008). Exosome function is determined 
by their cell-type-specific protein and miRNA cargoes as 
such, modulation and regulation of vascular homeostasis, 
antigen presentation to T cells, cytokine transport, but also 
progression of disease processes by transfer of oncogenes, 
infectious cargo (such as HIV particles) or pathogenic 
proteins between neurons (Schorey & Bhatnagar 2008). 
Exosomes are then natural carriers of RNA constituting 
potential delivery vehicles for exogenous nucleic acid 
cargoes. Exosomes purified from dendritic cells and 
targeting neuronal components were used as vehicles of 
siRNA delivery and were able to deliver them into the 
brain (Alvarez-Erviti et al. 2011). These results show 
that exosomes promise to revolutionise the field of drug 
delivery by enabling drug delivery across otherwise 
impermeable biological barriers (Lakhal & Wood 2011).
Aptamers
 Aptamers are nucleic acid-based molecules 
that bind to a specific target molecule such as small 
molecules, proteins, nucleic acids, and even cells and 
tissues. RNA-aptamers/siRNA chimeras allow better 
tissue internalization and amenability for modifications, 
make it an appropriate strategy for induction of targeted 
RNAi delivery in vivo (Daka & Peer 2012). This systems 
has been shown to specifically inhibit tumor growth in 
a mouse prostate cancer model (McNamara et al. 2006). 
An aptamer/siRNA chimera anti-gp120, in which both 
aptamer and siRNA portions directed against HIV genes, 
was used to specifically target cells expressing HIV 
receptor gp120 leading to repression of HIV replication 
in tissue culture tests (Zhou et al. 2008). These interesting 
results make this system an attractive approach for 
systemic RNAi application.
Other chemical vectors
 Aptamers are RNA or DNA oligonucleotides 
that fold by intramolecular interaction into unique three-
dimensional conformations capable of binding to target 
antigens with high affinity and specificity (Muratovska 
& Eccles 2004). The aptamers have been used as siRNA 
vectors in a mouse tumor xenograft model, however their 
systemic use requires addition of nuclease stabilizing 
agents and endosmolytic functionalities (Golzio et al. 
2007). Dendrimer molecules are repeated branched 
species characterized by structural perfection (Golzio 
et al. 2007). Dendrimers have been used successfully 
for in vitro delivery of siRNAs (Simeoni et al. 2003). 
Polyethyleneimines (PEI) are  polycation-containing 
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block copolymers (Muratovska & Eccles 2004), which 
have also been used for delivery of siRNA molecules in 
vivo, although PEI use in vivo has some toxicity issues 
(Crombez et al. 2009). Chitosan is a biodegradable, 
biocompatible and non-toxic cationic polymer obtained 
from deacetylation of chitin, which has been proposed as 
biocompatible alternative to cationic polymers, suitable 
for non-viral nucleic acid delivery (Crombez et al. 2007). 
Chitosans have been used for siRNA delivery in vitro as 
well as in vivo (Kumar et al. 2008). Antibody-protamine 
fusion carriers have also been shown to be efficient 
in delivery of siRNA to HIV-infected or envelope-
transfected leukocytes (Anantpadma et al. 2010). 
Viral vectors
 Like chemical vectors, the viral vector based 
delivery of shRNA also profited from technology that 
already existed for gene therapy. Soon after delivery of 
siRNAs in vitro (Bitko & Barik 2001), it was demonstrated 
that siRNAs can also be expressed from plasmid DNA as 
“short hairpin RNAs” (shRNAs) (Brummelkamp et al. 
2002; Paddison et al. 2002). This finding paved the way 
for viral vector based RNAi therapeutics. U6 (Paddison 
et al. 2002) and H1 (Brummelkamp et al. 2002) were 
the first polymerase III promoters described that could 
express functional siRNAs (González-Rojas et al. 2010). 
However U6 promoters have been reported to be more 
efficient in vivo (Makinen et al. 2006). Typically, shRNA 
transcription starts in a position outside the promoter 
sequence, continues along 19-29 nucleotide long top 
strand, the 4-19 nucleotide long hairpin loop and finally 
the bottom strand and terminates after the second or third 
residue of track of 4-6 thymidines (González-Rojas et al. 
2010). The termination is so designed that it results in a 
3’ two- nucleotide overhang after RNAse III cleavage as is 
the case with natural pre-miRNAs (González-Rojas et al. 
2010). The shRNA sequences are selected and translated 
to DNA, and these are normally synthesized in the form 
of two complimentary oligonucleotides that are annealed 
and cloned downstream of the selected promoter and 
regulatory sequences (González-Rojas et al. 2010). The 
constructed shuttle plasmids expressing shRNA are next 
tested for inhibition of target gene in vitro. Moreover, 
the cassettes may be inserted into expression clones for 
production of required recombinant virus vectors. In 
addition to standard shRNA resulting in production of a 
21 nt long siRNAs, numerous other variations of shRNA 
have also been used. Longer shRNAs producing 27- 29 nt 
long siRNAs (Kim 2005; Siolas et al. 2005), and multiple 
shRNAs simultaneously expressing different shRNAs 
against different target regions have been used (Liu et al. 
2008; Aagaard et al. 2008). The viral vectors have certain 
advantages over chemical vectors for delivery of siRNAs 
like (González-Rojas et al. 2010); 
1. Tissue specific delivery of shRNAs.
2. Possibility of inducible or tissue specific 
promoters.
3. Both transient as well as stable expression of 
shRNA is possible, according to the viral vector chosen.
4. Better transduction efficiency compared to non-
viral transfections even in cells like lymphocytes that are 
traditionally hard to transfect.
5. Cost effectiveness.
6. Most of the available viral vectors have already 
been tested clinically in phase I safety trials.
 The most widely used viral vectors for shRNA 
delivery include adenovirus, adeno associated virus 
(AAV), lentivirus, retrovirus, and baculovirus. In 
contrast to the gene therapy, shRNA expressing cassettes 
tend to be of small length and their expression is possible 
even by the smallest vectors (González-Rojas et al. 2010). 
However, viral vectors are selected on the basis of tissues 
required to be transduced and also whether stable or 
transient transduction is required. For chronic infections 
like HIV stable transduction is desirable to avoid repeated 
administration of vectors while for acute infections, 
transient transductions with shRNA expressing vectors 
would suffice. The RNA viruses such as retrovirus and 
lentivirus produce stable transduction as they integrate 
into host genomes while non-integrating DNA viruses 
like adenovirus, baculovirus and AAV maintain their 
genome episomally in the host cells. 
 For gene therapy as well as for RNAi, replication 
defective adenoviruses can be used since they are non-
pathogenic and can transiently transduce a variety of 
both dividing and non-dividing cells without integration 
to the host genome (González-Rojas et al. 2010). 
Adenoviral vectors
 In the past it has been considered that adenovirus 
serotypes belonging to species A, C, D, E and F use the 
coxsackie and adenovirus receptor (CAR) as a docking 
site providing a high affinity virus-to-host association 
(Roelvink et al. 1998).  CAR was previously thought to 
be a primary Ad5 receptor, but now there are studies 
according to which adenovirus type 5 also uses many 
other receptors for docking like the heparan sulfate 
proteoglycan (HSPG), vascular cell adhesion molecule 
1 (VCAM-1), major histocompatibility complex class I 
(MHC 1), scavenger receptors (SR), while indirect binding 
it also uses dipalmitoyl phosphatidylcholine receptors 
(DPPCRs), coagulation factor X (FXs), and Lactoferrin 
receptors (LfRs) (Arnberg 2009). Although receptor 
binding is thought to play a major role in adenoviral 
tropism, this alone cannot explain all aspects of in vivo 
host-virus interactions like enhanced transductions of 
liver cells or adenoviral uptake by Kupffer cells (Sharma 
et al. 2009). Excessive adenoviral binding to hepatocytes 
may be partly explained by binding of central depression 
of adenoviral hexon with Gla domain of coagulation 
factor X (FX) which has been found to produce efficient 
transduction of hepatocytes (Kalyuzhniy et al. 2008). 
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That may explain excessive liver tropism of adenovirus 
where FX could be the main determinant of in vivo liver 
transduction (Kalyuzhniy et al. 2008).
 The internalization of adenovirus occurs by a 
secondary interaction between RGD motifs on penton 
base protein and integrins αvβ3 and αvβ5 (Wickham 
et al. 1993) through clathrin-coated pits mediated 
endocytosis (Wang et al. 1998). The virus then escapes 
by lysing endosomal membrane and with the help of 
microtubule mediated translocation, enter the nuclear 
pore complex where viral DNA is released for expression 
(Barnett et al. 2002). The transcription of wild type virus 
initiates with expression of early E1 genes, which activate 
synthesis of viral genes and replication. E1 and the 
non-essential E3 genes were deleted in first generation 
adenoviral vectors to render them replication deficient 
(González-Rojas et al. 2010). But these first-generation 
adenoviruses express viral genes to low levels, including 
virus associated (VA) RNAs which have been described 
to saturate the cellular silencing machinery, leading to 
toxicity (Andersson et al. 2005). Although functional 
inhibitory exogenous shRNAs have been expressed for 
first generation adenoviral vectors without saturation of 
silencing machinery (Narvaiza et al. 2006). The second 
generation vectors, which have deletions in the E1-E4 
locus are comparatively less immunogenic and show 
prolonged expression of recombinant genes (Gao et 
al. 1996). Whereas third generation adenoviruses are 
produced by deleting all the viral genes, as a result of 
which expression of viral genes is avoided resulting in 
lesser immunogenicity (Schiedner et al. 1998).
 The recombinant replication deficient 
adenoviruses have been successfully used in vitro as 
shRNA delivery vectors against numerous viruses like 
hepatitis B virus (Uprichard et al. 2005), measles virus 
(Otaki et al. 2007), hepatitis C virus (Sakamoto et al. 
2008), dengue virus (Korrapati et al. 2012) and the 
animal peste des petits ruminants virus (PPRV) (Nizamani 
et al. 2011).  The adenoviral vectors expressing shRNA 
have been successfully used in vivo against several 
viral infections. After pre-treatment of  guinea pigs 
and swine with adenoviral vectors expressing shRNA 
against foot and mouth disease virus (FMDV), and 
challenging 24 hours later with the target virus, Chen and 
colleagues could protect the animals from major clinical 
manifestation of the disease (Chen et al. 2006). Similarly 
adenoviral vectors have also been used to protect mice 
against porcine circovirus type 2 (Feng et al. 2008).
Baculoviral vectors
 Among the numerous baculoviruses, Autographa 
californica multiple nucleopolyhedrovirus (AcMNPV) is 
the most well studied and extensively used virus for foreign 
gene expression (Hu 2005). AcMNPV possesses a circular 
double stranded DNA genome which is condensed into a 
nucleocapsid core by a protamine-like protein. Naturally 
AcMNPV are occluded in a polyhedron which after 
being ingested by insects is dissolved in alkaline midgut, 
releasing infectious virions (Hu 2005). The AcMNPVs 
only replicate in insect cells and naturally infect insects 
belonging to the order Lepidoptera. Baculoviruses 
primarily enter insect cells through clathrin-mediated, 
low-pH dependent endocytic pathway while they may 
enter mammalian cells through multiple pathways 
including caveola-dependent mechanism as well (Long 
et al. 2006). However, AcMNPV can infect insect cells 
and transduce mammalian cells even in the absence of 
endocytosis, by direct fusion at cell surface under low pH 
conditions (Dong et al. 2010). 
 The baculoviruses can enter the mammalian 
cells but they are unable to express their genes because 
the baculovirus promoters are inactive in these cells 
(Kost & Condreay 2002). One of the interesting 
consequences of this is the absence of pre-existing 
antibodies against baculovirus in mammals (Kost & 
Condreay 2002; Volkman & Goldsmith 1983). For gene 
transfer and expression in mammalian cells, so-called 
BacMam viruses have been generated by incorporation 
of mammalian cell-active expression cassettes (Kost et al. 
2010). BacMam baculoviruses are capable of transducing 
wide variety of cells including non-dividing cells (van 
Loo et al. 2001) and primary cells (Sarkis et al. 2000). 
They  have been used to reduce viral infections in vitro 
of numerous viruses like porcine arterivirus (Chen et al. 
2006), PPRV (Nizamani et al. 2011), hepatitis C virus 
(Suzuki et al. 2008), hepatitis B virus (Starkey et al. 2009), 
and influenza viruses A and B (Suzuki et al. 2009). 
 The baculovirus can prove to be good shRNA 
delivery vectors in vivo. Although delivery of siRNA to the 
appropriate cells or tissues is a major challenge, problem 
of inactivation by complement is resolved (Hofmann 
& Strauss 1998). Chemical or genetic modification can 
also overcome problem of serum inactivation (Yang et 
al. 2009; Kaname et al. 2010). Furthermore, it is reported 
that baculoviruses do not have deleterious effects on 
mammalian cells even when used at very high multiplicity 
of infections (MOIs) (Andersson et al. 2007). Moreover, 
not only can the baculoviruses be easy and cheap to 
produce, they can be grown to high titers in cell cultures 
as well. Although baculovirus vectors have not been used 
thus far for shRNA delivery in vivo, but these have been 
successfully used for gene transfer into mouse brain and 
rabbit retina (Lehtolainen et al. 2002; Kinnunen et al. 
2009).
Other viral vectors
 Many other viral vectors have been used for 
RNAi mediated silencing of viral infections like adeno-
associated virus (AAV) (Moore et al. 2005), herpes 
simplex virus (Lambeth et al. 2009), retroviruses 
(Brummelkamp et al. 2002), and lentiviruses (Banerjea 
et al. 2003). Moreover, these viral vectors have also been 
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used against infectious disease of veterinary importance. 
Infectious bursal disease virus (IBDV) by an avian adeno 
associated virus delivered miRNAs targeting VP1 and 
VP2 genes in vitro (Wang et al. 2009). Recombinant 
herpesvirus of turkey (HVT) expressing shRNAs against 
genes gB and UL29 of the Marek’s disease virus (MDV) 
moderately reduced viremia in chicken (Lambeth et 
al. 2009). In another study, avian leukosis virus-based 
retroviral vectors expressing shRNA against MDV gB 
glycoprotein gene and ICP4 transcriptional regulatory 
gene could significantly reduce MDV viremia in vivo 
(Chen et al. 2009).
Ex-vivo delivery
 si/shRNAs are often delivered to target cell ex-
vivo, and these modified cells are then re-injected back 
into the patients (Abdel-Wahab et al. 2005; DiGiusto et 
al. 2010).
Self-delivering compounds
 Scientists at RXi Pharmaceuticals Corporation 
have used an alternative approach to delivery RNAi drugs. 
They have developed chemically modified RNAs that can 
enter cells without a vehicle. These novel compounds are 
termed ‘self-delivering’ RNAi compounds or sd-rxRNA 
(Plane 2010). sd-rxRNAs are hybrid oligonucleotide 
compounds that are able to bind cells, uptake and release 
into them. It has a single-stranded phosphorothioate 
region, a short duplex region, and contains a variety 
of nuclease-stabilizing and lipophilic chemical 
modifications combining the cellular uptake properties 
and favorable tissue distribution of the single-stranded 
RNA and the intracellular potency of the double-stranded 
RNAi compounds. In addition, chemical modifications 
give it a long-lasting intracellular activity. RXi promises 
that these next-generation RNAi drugs, designed for 
therapeutic use, have drug-like properties, such as high 
potency, target specificity, serum stability, reduced 
immune response activation and efficient cellular uptake. 
Modified siRNA compounds
 Most siRNAs used in research today are chemically 
synthesized as single-stranded oligonucleotides and then 
annealed into double-stranded form. This approach 
permits incorporation of a wide variety of modifications 
that can help solve some problems associated with 
administration of siRNA into cells or in vivo organisms. 
Some problems that can be addressed using modification 
include:
1. Susceptibility to nuclease degradation
2. Activation of off-target effects
3. Cell uptake and pharmacokinetics.
 The kind of modifications to employ have to be 
chosen based on the design of the siRNA used, specific 
sequence, intended application, and method of delivery. 
Blunt-ended 27-nt dsRNAs, which are cleaved by 
Dicer to lead to the release of 21-nt siRNAs, exhibited 
a higher gene-silencing effect than 21-nt siRNAs (Kim 
et al. 2005). Dicer-substrate siRNA (DsiRNA), which 
is an asymmetric duplex RNA composed of a 25-nt 
sense strand with a blunt-end at the 3´-end and a 27-
nt antisense stand with a 2-nt overhang at the 3´-end 
(25D/27-nt), could be directly cleaved by Dicer in a 
single 21-nt siRNA product, and exhibited a potent gene-
silencing effect (Amarzguioui et al. 2006). Although 
these results, structural modifications of siRNAs are 
not enough to solve problems of poor cell uptake and 
low resistance against nuclease degradation. Protection 
against nuclease degradation can be provided externally 
through use of a delivery vehicle such as liposomes, 
peptides or nanoparticles, or intrinsically through 
chemical modifications of the nucleic acid itself.
3’-dTdT overhangs
 The single-stranded 3’-overhangs present in 
traditional 21-mer siRNA designs are particularly 
susceptible to nuclease degradation that probably 
initiates its attack at the 3’-overhangs and proceeds in a 
3 → 5´direction (Zou et al. 2008). Deoxythymidine (dT) 
or another deoxyribonucleotide overhang protect against 
exonuclease degradation (Elbashir et al. 2001). However, 
this outlook has no unanimity.  Strapps and colleagues 
(Strapps et al. 2010), for example, have demonstrated that 
the thymidine overhangs are consistently detrimental 
to obtaining maximum duration of silencing from the 
siRNAs both in vitro and in vivo and should therefore be 
avoided for any siRNA that is intended to be developed 
for therapeutic purposes or for extended action in any 
context. The authors exactly argue that the presence of 
thymidine residues may expose the siRNA to DNAses. 
It is also possible that dTdT overhangs bind less stably 
to the Argonaute (Lee et al. 2007), and thus reducing the 
stability of RISC complexes. 
Chemical modifications
 Several chemical modifications, extensively 
used in antisense oligonucleotides, can be potentially 
employed in siRNAs to improve nuclease stability. 
Modifying directly the internucleotide phosphate 
linkage by replacing an oxygen with sulfur (PS), boron 
(boranophosphate), nitrogen (phosphoramidate), or 
metyl (methylphosphonate groups can provide nuclease 
resistance to siRNAs (Behlke 2008). 
 Modification of the 2’-position of the ribose can 
also improve nuclease resistance of the internucleotide 
phosphate bond and increase duplex stability. This 
modification can be acquired by 2’-O-methyl (2’OMe), 
2’-fluoro (2’-F), 2’-O-(2-methoxyethyl) (2’-MOE) or 
2’-fluoro-ß-D-arabinonucleotide (FANA) incorporation 
at specific positions of sense or antisense strands (Allerson 
et al. 2005; Choung et al. 2006; Dowler et al. 2006). These 
modifications can be combined for improving stability in 
serum and in vivo performance (Behlke 2008). 
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 Locked nucleic acids (LNAs) which contain a methylene bridge linking the 2’-O with the 4’C of the ribose 
and “locking” the sugar in the 3’-end conformation provide both duplex stability and nuclease resistance to siRNAs 
(Grunweller et al. 2003; Mook et al. 2007).
Table 1. RNAi antiviral therapeutics currently in clinical trials*.
Clinical 
setting Drug Disease Target(s) Delivery/Vehicle Company Status
Antiviral
ALN-RSV01 RSV in volunteers RSV nucleocapsid Naked siRNA in intranasal adminstration Alnylam Pharm
Completed, 
Phase II
ALN-RSV01 RSV in lung transplant patients RSV nucleocapsid Naked siRNA by nebulization Alnylam Pharm
Completed, 
Phase I
ALN-RSV01 RSV in lung transplant patients RSV nucleocapsid Naked siRNA by nebulization Alnylam Pharm Active, Phase II
ALN-RSV01 RSV in lung transplant patients RSV nucleocapsid Naked siRNA by nebulization Alnylam Pharm Active, Phase II
pHIV7-shl-
TAR-CCR5RZ HIV-1 in infected patients








AVI-7100 Influenza A (H1N1) in heal thy volunteers
Influenza A virus M1 and 
M2 genes
siRNA incorporated into 
PMOplusTM per infusion
AVI Biopharma 
Inc. Active, Phase I
TKM-Ebola Ebolavirus Ebolavirus L polymerase, VP24 and VP35 genes
siRNA incorporated  into 
lipid nanoparticle intravenous 
injection
Tekmira Pharm. 
Corp. Active, Phase I
RSV, respiratory syncytial virus; PMOplusTM phos phor odiami date mor pholino oligomer containing three modifi ed  linkages ; 
CR5RZ, host T cell CCR5 cytokine receptor.
* From www.clinicaltrials.gov
 The 2’OMe modification is a naturally occurring 
RNA variant and its use in synthetic siRNAs is not 
expected to present significant toxicity (Behlke 2008). 
Contrarily, 2’-F, 2’-MOE or FANA modifications are not 
naturally occurring and their potential toxicity, therefore, 
needs to be considered. To date, no evident toxicity has 
been observed after using of 2’-F nucleic acids in vivo. In 
contrast, some dose-dependent hepatic toxicity has been 
reported when LNA-oligonucleotides were administrated 
to mice (Fluiter et al. 2003; Swayze et al. 2007).
 The presence of specific chemical modifications, 
including those present in mammalian tRNAs and 
rRNAs as pseudouridine, N6-methyl-A, 2’OMe and 2’-F 
modified ribose, can allow synthetic siRNAs to evade 
immune response (Behlke 2008). Inclusion of only two 
or three 2’OMe modified residues in an RNA duplex 
can be sufficient to prevent immune activation, and 
modification of rU or rG residues is most effective (Judge 
et al. 2006).   
 A single 2’OMe residue at position 2 of the guide 
strand may also reduce or abolish off-target effect due to 
the participation of siRNAs in miRNA pathways (Jackson 
et al. 2006b). Replacement of entire seed region by DNA 
residues may similarly maintain wanted silencing of 
target genes while reduce off-target knockdown related 
with the homology of the seed region of siRNA (Ui-Tei et 
al. 2008a).   
Future directions and conclusions
 Optimism over the potential for RNAi 
therapeutics remains undiminished despite the numerous 
obstacles encountered since its discovery. In theory, 
siRNAs have extraordinary abilities as to be developed 
to silence any gene; to be developed incredibly fast; to 
have picomolar efficacy; to have an effect that may last 
for weeks. Nevertheless, vari¬ous complex barriers to 
achieving efficient therapy based on RNAi have become 
evident. These hurdles include: specificity for the target 
gene; stability of the siRNAs; and delivery to the correct 
cell or tissues. With the emergence of newer technologies 
such as chemical modification of siRNAs, non-specific 
effects, degradation and difficulties with delivery of 
siRNAs may become manageable. Although the clinical 
utility of RNAi has not yet been concretized, encouraging 
results have been provided by a number of patient trials, 
notably for treating skin, cancers, ocular and kidney 
disorders, and viral infections. To date, there have been 
more than 32 clinical trials involving 16 diseases and 23 
different siRNA or shRNAs, seven of them against viral 
diseases (Table 1). Moreover, since 2008, the development 
pipeline has not only grown in size (18 active clinical 
candidates today), but more importantly it has improved 
in quality concomitant with a shift from local to systemic 
delivery: 7 of the 14 new clinical candidates since 2008 
were delivered systemically, compared to only 1 of the 
8 before (Haussecker 2012). This is largely the result of 
the clinical entry of the most advanced systemic delivery 
platforms, stable nucleic acid lipid particles (SNALP) 
and AtuPLEX. SNALP alone accounts for six clinical 
candidates (ALN-VSP02, TKMApoB, ALN-TTR01, 
TKM-PLK1, ALN-PCS02, TKM-EBOLA) and one 
more is expected to enter the clinic in the near future 
(ALN-TTR02). Up to now, more advanced results have 
been obtained targeting accessible tissues such as liver, 
skin or ocular mucosa because delivery still remains the 
most significant barrier to the widespread use of RNAi 
15RNA Interference As Antiviral Therapy: Dream Or Reality?
therapeutics.  
 In summary, although the clinical applications 
of RNAi technology have not yet been fully conquered 
it has made extraordinary progress in less than fifteen 
years since the first demonstration of gene silencing in 
mammalian cells. Many hurdles remain for using RNAi-
based therapeutics, one of the most significant one being 
probably delivery. However, very encouraging results are 
showing how far RNAi technology will go.
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